Eli Lilly diabetes drug Mounjaro won UK watchdog backing: Bloomberg
Britain: Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.Mounjaro is expected to become a blockbuster treatment if it is also approved to treat obesity and a U.S. decision on its use for weight loss is expected later this year.Bloomberg News quoted Helen Knight, director of...
Britain: Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.
Mounjaro is expected to become a blockbuster treatment if it is also approved to treat obesity and a U.S. decision on its use for weight loss is expected later this year.
Bloomberg News quoted Helen Knight, director of medicines evaluation at the National Institute for Health and Care Excellence (NICE) as saying that Mounjaro has the potential to "provide an effective and good value treatment option" for people with type 2 diabetes that isn't well controlled by other drugs.
NICE and Lilly did not immediately respond to a Reuters request for comment.
Earlier in July, NICE did not recommend Mounjaro, also known as tirzepatide, saying more evidence was needed before it could be used by the National Health Service. NICE asked Lilly for more data on whether the drug resulted in better weight loss than other drugs belonging to the same class of treatments.
Read also: Europe to face shortage of Eli Lilly diabetes drug Trulicity through September
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd